Structure Therapeutics Inc. American Depositary Shares (GPCR) - Total Assets
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) holds total assets worth $1.58 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GPCR book value for net asset value and shareholders' equity analysis.
Structure Therapeutics Inc. American Depositary Shares - Total Assets Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's total assets have evolved over time, based on quarterly financial data.
Structure Therapeutics Inc. American Depositary Shares - Asset Composition Analysis
Current Asset Composition (December 2025)
Structure Therapeutics Inc. American Depositary Shares's total assets of $1.58 Billion consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GPCR stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Structure Therapeutics Inc. American Depositary Shares's current assets represent 99.1% of total assets in 2025, a decrease from 99.3% in 2020.
- Cash Position: Cash and equivalents constituted 50.5% of total assets in 2025, up from 42.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Structure Therapeutics Inc. American Depositary Shares Competitors by Total Assets
Key competitors of Structure Therapeutics Inc. American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Structure Therapeutics Inc. American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.81 | 24.74 | 12.62 |
| Quick Ratio | 24.81 | 24.74 | 12.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.51 Billion | $855.19 Million | $100.59 Million |
Structure Therapeutics Inc. American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Structure Therapeutics Inc. American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.55 |
| Latest Market Cap to Assets Ratio | 1.89 |
| Asset Growth Rate (YoY) | 75.3% |
| Total Assets | $1.58 Billion |
| Market Capitalization | $2.99 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Structure Therapeutics Inc. American Depositary Shares's assets above their book value (1.89x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Structure Therapeutics Inc. American Depositary Shares's assets grew by 75.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual total assets of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.58 Billion | +75.34% |
| 2024-12-31 | $903.33 Million | +87.41% |
| 2023-12-31 | $482.02 Million | +392.63% |
| 2022-12-31 | $97.84 Million | -11.97% |
| 2021-12-31 | $111.16 Million | +187.19% |
| 2020-12-31 | $38.70 Million | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more